c/o Avena Partners AB
Merozyne Therapeutics has been established to develop a treatment for MDC1A. The company has the following founders, who together form a highly complimentary and skilled project team:
Prof. Madeleine Durbeej-Hjalt and Dr. Virginie Carmignac are inventors of the technology and will contribute knowledge in disease biology, in vitro and in vivo assays.
Avena Partners AB: Expertise in project management, business development, business intelligence and IPportfolio management.
Kombinator AB: Expertise in business development and financing.
Red Glead Discovery AB: Drug discovery company focused on small molecules and peptides. Founded 2011 by AstraZeneca co-workers. Strong laboratory skills in medicinal chemistry, custom synthesis, in vitro biology and ADME combined with project management and patent strategy expertise.
SARomics Biostructures AB is the leading structural biology provider in northern Europe and has built a global reputation for its structure-based drug design skills and protein structure determination capabilities. Recently the company opened a US sales office in Boston. In parallel the company has attracted significant funding for its internal research programs and is currently involved in three international research initiatives aiming at the discovery of leads for new medicines.
For further information and contact details please visit www.merozyne.com.
CEO: Eskil Söderlind
CTO: Björn Walse
CSO: Madeleine Durbeej-Hjalt
COB: Tomas Eriksson